An expert discusses the current treatment landscape of Rett syndrome including the goals of treatment and implications for utilization management strategies with the disease. David Lieberman, MD, PhD: ...

Credit: Acadia Pharmaceuticals. The approval was supported by data from the randomized, double-blind, placebo-controlled phase 3 LAVENDER study. The Food and Drug Administration (FDA) has approved ...

-- First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S. 1 SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc.

An expert highlights unmet needs in the treatment of Rett syndrome. Paige Nues: The biggest unmet need for Rett syndrome is that there is no intervention or cure for this disorder. Onset is between 6 ...

Trofinetide is a novel synthetic analogue of the amino-terminal tripeptide of IGF-1 designed to reduce neuroinflammation and supporting synaptic function. A New Drug Application (NDA) for trofinetide ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett ...

Biomed Industries, Inc. to Present Promising NA-921 Phase 2/3 Results for Rett Syndrome Treatment at EAPS Conference, October 18-20, 2025 in Lisbon, Portugal. The Phase 2/3 results of NA-921 show ...

Acadia Pharmaceuticals announced last Friday that the FDA approved DAYBUE (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the ...

Feb. 11 -- TUESDAY, Feb. 10 (HealthDay News) -- Researchers may have found a new treatment for Rett syndrome, a rare inherited disease in girls that brings on autism-like symptoms along with heart and ...

As the JR Group toasts its 30th anniversary, a celebratory dinner in Glasgow will channel the firm's success into a powerful ...